First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Slide 62 VictozaⓇ maintains a 14% value market share in the GLP-1, SGLT-2 and DPP-IV segment Segment value Share of segment value growth Segment value market shares 100 50 DKK billion 250 100% 12% 12% 200 80% CAGR¹ value: 26.4% 150 60% 40% VictozaⓇ Other GLP-1 SGLT-2 DPP-IV 100% 80% 60% 40% VictozaⓇ: 14% 20% 20% 0% 0% Feb 2013 Feb 2018 2016 vs 2017 2017 vs Feb 2018 2013 Feb 2018 1 CAGR for 5-year period Note: Segment only includes DPP-IV, GLP-1 & SGLT-2. Other oral anti-diabetic agents and insulin excluded Source: IQVIA MAT Feb, 2018 value figures changing diabetes® novo nordisk

View entire presentation